Acadia Pharmaceuticals (ACAD) Capital Expenditures (2012 - 2026)

Acadia Pharmaceuticals' Capital Expenditures history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 1793.31% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 796.75% from the prior year.
• Capital Expenditures grew to $5.2 million in Q1 2026 per ACAD's latest filing, from $4.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $5.2 million in Q1 2026 and bottomed at $70000.0 in Q3 2024.
• The 3-year median for Capital Expenditures is $420500.0 (2024), against an average of $1.7 million.
• Biggest YoY gain for Capital Expenditures was 784.11% in 2025; the steepest drop was 454.29% in 2025.
• Year by year, Capital Expenditures stood at $453000.0 in 2024, then soared by 784.11% to $4.0 million in 2025, then soared by 30.14% to $5.2 million in 2026.
• Per Business Quant, the three latest ACAD Capital Expenditures figures stand at $5.2 million (Q1 2026), $4.0 million (Q4 2025), and $388000.0 (Q3 2025).